Mandella Chrispus

Health care professional with over seven years of experience in pharmaceutical services within health care and clinical research. Broad background in pharmacy and public health, specializing in Good Clinical Practices, public health research interventions, vaccines, and clinical supplies management. Experienced in managing research projects, Uganda’s health care structure, quality management systems, and monitoring public health interventions. Previous roles include Regulatory and Research pharmacist positions involving supporting regulatory compliance, conducting interventional studies, designing quality management systems, overseeing pharmacy operations, and supervising pharmacy staff.

Pharmaceutical Society of Uganda (Registration no. 930)

• Pharmacist of Record, HPTN 084 protocol: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women.
• Pharmacist of Record, IAVI C100 protocol: Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults.
• Pharmacist of Record, CoVPN 3008 protocol: Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern.
• Pharmacist of Record, VAT00008 protocol: A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older.
• Pharmacist of Record, PURPOSE 1 protocol: A Phase 3, Double-Blinded, Multicenter, Randomized Study to Evaluate Safety and Efficacy of Twice Yearly Long-Acting Subcutaneous Lenacapavir, and Daily Oral Emtricitabine/Tenofovir Alafenamide for Pre-Exposure Prophylaxis in Adolescent Girls and Young Women at Risk of HIV Infection.
• Pharmacist of Record, COVAC-003 protocol: Randomized, Observer-Blind, Phase 2 Clinical Trial of COVAC-2 in Generally Healthy Adults.
• Pharmacist of Record, VPM1002-MN-3.05TB protocol: A multicenter, phase III, doubleblind, randomized, active-controlled study to evaluate the efficacy and safety of VPM1002 in comparison to BCG in prevention of Mycobacterium tuberculosis infection in newborn infants.
• Pharmacist of Record, PIP Trial: Praziquantel for children under age four years: A Phase II PK/PD driven dose finding trial.

• Introduction to Infection control and Prevention (IPC) by WHO
• ICH GCP (R2) Investigator Site Training by ICON / FIRECREST
• ICH GOOD CLINICAL PRACTICE E6 (R2)
• COVID-19 Bio-safety and Bio-security training
• Massive Online Course (MOOC) on Implementation Research
• Marine Basic Swimming and Water Survival Skills Course

1. Dr. Julius Turyatunga,

Pharmacy Operations Manager,

TATA UGANDA LIMITED,

Tel: +256 754 200959

Email: julius.turyatunga@tatainternational.com

2. Dr. Phiona Nabaggala,

Head Pharmacy Department,

MRC/UVRI and LSHTM Uganda Research Unit,

Tel: +256 775 876807

Email: Phiona.Nabaggala@mrcuganda.org

3. Dr. Sandra Mirembe Nankwanga,

Research Pharmacist,

UVRI-IAVI HIV VACCINE PROGRAM,

Tel: +256 788 485797

Email: SMirembe@iavi.or.ug